{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:05:49Z","timestamp":1784225149572,"version":"3.55.0"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010600","name":"Tays","doi-asserted-by":"publisher","award":["T63864"],"award-info":[{"award-number":["T63864"]}],"id":[{"id":"10.13039\/501100010600","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010600","name":"Tays","doi-asserted-by":"publisher","award":["T62604"],"award-info":[{"award-number":["T62604"]}],"id":[{"id":"10.13039\/501100010600","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010600","name":"Tays","doi-asserted-by":"publisher","award":["9AB015"],"award-info":[{"award-number":["9AB015"]}],"id":[{"id":"10.13039\/501100010600","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010744","name":"Pirkanmaan Sy\u00f6p\u00e4yhdistys","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010744","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The decision on appropriate adjuvant treatment for patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 -negative (HER2-) early breast cancer (eBC) is sometimes challenging. Genomic assays have improved individualized treatment decisions by providing information on the genomic risk of tumors. The Oncotype DX assay (ODX) is both prognostic and predictive of chemotherapy benefit. This study aimed to evaluate the implementation process of the ODX into clinical practice, the impact of ODX on adjuvant chemotherapy treatment decisions and conduct a cost impact analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>A retrospective study at Tampere University Hospital included 129 patients with HR\u2009+\u2009, HER2- eBC tested with ODX between September 2021 and September 2023. Treatment decisions as well as adjuvant chemotherapy (CT) costs, associated health provider costs, and societal costs were projected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ODX testing significantly altered CT recommendations by reducing unnecessary CT for 73% of the study patients. With ODX testing, the cost impact analysis revealed partial cost savings for the health care provider due to reduced CT administration. From a societal perspective, the use of ODX resulted in substantial savings largely attributed to the maintenance of work productivity among working-aged and employed patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study highlights the importance of streamlined testing processes and the need for clinician training in interpreting test results in a real-world setting. In addition, the findings underscore the role of ODX in enhancing personalized treatment in HR\u2009+\u2009, HER2- eBC while reducing overtreatment. The cost analysis indicates substantial cost savings with ODX testing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0353941","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:34:17Z","timestamp":1784223257000},"page":"e0353941","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world implementation and cost impact analysis of Oncotype DX testing in early-stage breast cancer"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4983-1879","authenticated-orcid":true,"given":"Niina","family":"M\u00e4enp\u00e4\u00e4","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4247-8523","authenticated-orcid":true,"given":"Leena","family":"Tiainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Martikainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arja","family":"Jukkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarit","family":"B\u00e4rlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"pone.0353941.ref001","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 2.2024. https:\/\/www.nccn.org\/"},{"issue":"2","key":"pone.0353941.ref002","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"S Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"pone.0353941.ref003","unstructured":"Finnish Breast Cancer Group. National treatment guideline for breast cancer diagnostics and treatment. 2024. https:\/\/rintasyoparyhma.yhdistysavain.fi\/hoitosuositus\/"},{"issue":"27","key":"pone.0353941.ref004","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"S Paik","year":"2004","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0353941.ref005","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.2009.24.4798","article-title":"Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study","volume":"28","author":"M Dowsett","year":"2010","journal-title":"J Clin Oncol"},{"issue":"23","key":"pone.0353941.ref006","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer","volume":"24","author":"S Paik","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"pone.0353941.ref007","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","article-title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial","volume":"11","author":"KS Albain","year":"2010","journal-title":"Lancet Oncol"},{"issue":"25","key":"pone.0353941.ref008","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer","volume":"385","author":"K Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0353941.ref009","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer","volume":"379","author":"JA Sparano","year":"2018","journal-title":"N Engl J Med"},{"key":"pone.0353941.ref010","article-title":"Long term side effects of adjuvant chemotherapy in patients with early breast cancer","author":"JJ Tao","year":"2015","journal-title":"Breast"},{"issue":"2","key":"pone.0353941.ref011","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4048\/jbc.2013.16.2.229","article-title":"Does chemotherapy really affect the quality of life of women with breast cancer?","volume":"16","author":"SY Hwang","year":"2013","journal-title":"J Breast Cancer"},{"issue":"3","key":"pone.0353941.ref012","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1001\/jamaoncol.2015.3856","article-title":"Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer","volume":"2","author":"M Chavez-MacGregor","year":"2016","journal-title":"JAMA Oncol"},{"issue":"7","key":"pone.0353941.ref013","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1002\/cam4.2830","article-title":"Impact of delayed treatment in women diagnosed with breast cancer: A population-based study","volume":"9","author":"PJ Ho","year":"2020","journal-title":"Cancer Med"},{"issue":"9","key":"pone.0353941.ref014","doi-asserted-by":"crossref","DOI":"10.1200\/JOP.2017.023788","article-title":"Implementation of Surgeon-Initiated Gene Expression Profile Testing (Onco type DX) Among Patients With Early-Stage Breast Cancer to Reduce Delays in Chemotherapy Initiation","volume":"13","author":"K Losk","year":"2017","journal-title":"J Oncol Pract"},{"key":"pone.0353941.ref015","unstructured":"Health Information and Quality Authority. A rapid health technology assessment of gene expression profiling tests for guiding the use of adjuvant chemotherapy in early-stage breast cancer. 2024. https:\/\/www.hiqa.ie\/reports-and-publications\/health-technology-assessment\/rapid-hta-gene-expression-profiling-tests"},{"key":"pone.0353941.ref016","unstructured":"Tampere University Hospital Costing Manual. 2022."},{"key":"pone.0353941.ref017","unstructured":"The Database of Pharmaceutical Preparations of the Association of Finnish Pharmacies (AFP). https:\/\/www.apteekkariliitto.fi\/en\/b-to-b-services.html 2024 July 6."},{"key":"pone.0353941.ref018","unstructured":"The Social Insurance Institution of Finland K. Kela\u2019s Info Tray \u2013 Source for Kela\u2019s research and statistics information. https:\/\/tietotarjotin.fi\/en\/front-page 2024 July 6."},{"issue":"12","key":"pone.0353941.ref019","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S1470-2045(09)70307-9","article-title":"Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial","volume":"10","author":"H Joensuu","year":"2009","journal-title":"Lancet Oncol"},{"issue":"3","key":"pone.0353941.ref020","first-page":"298","article-title":"Sick Leave Related Productivity Loss","volume":"120","author":"AJ Tanskanen","year":"2024","journal-title":"Kansantal Aikakausk"},{"issue":"8","key":"pone.0353941.ref021","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer","volume":"375","author":"F Cardoso","year":"2016","journal-title":"N Engl J Med"},{"key":"pone.0353941.ref022","doi-asserted-by":"crossref","first-page":"5909724","DOI":"10.1155\/2022\/5909724","article-title":"Cost and Clinical Benefits Associated with Oncotype DX\u00ae Test in Patients with Early-Stage HR+\/HER2- Node-Negative Breast Cancer in the Netherlands","volume":"2022","author":"FE de Jongh","year":"2022","journal-title":"Int J Breast Cancer"},{"key":"pone.0353941.ref023","doi-asserted-by":"crossref","first-page":"1191943","DOI":"10.3389\/fonc.2023.1191943","article-title":"Genomic signature to guide adjuvant chemotherapy treatment decisions for early breast cancer patients in France: a cost-effectiveness analysis","volume":"13","author":"E Curtit","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"pone.0353941.ref024","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10549-021-06211-w","article-title":"Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland","volume":"188","author":"LM McSorley","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"pone.0353941.ref025","unstructured":"Finnish Cancer Registry. https:\/\/cancerregistry.fi\/information\/ 2024 October 5."},{"issue":"12","key":"pone.0353941.ref026","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.6004\/jnccn.2016.0163","article-title":"Factors Associated With Delays in Chemotherapy Initiation Among Patients With Breast Cancer at a Comprehensive Cancer Center","volume":"14","author":"K Losk","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"pone.0353941.ref027","unstructured":"Finnish Institute for Health and Welfare. Surveillance of treatment access among cancer patients: Definitions and instructions: Effective from 20170101. 2017. https:\/\/urn.fi\/URN:ISBN:978-952-302-782-4"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0353941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:34:25Z","timestamp":1784223265000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0353941"}},"subtitle":[],"editor":[{"given":"Udayan","family":"Bhattacharya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0353941","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]}}}